Uptake of Long Acting Reversible Contraceptives at a Tertiary Hospital in South-South Nigeria: A 3-Year Review.
Main Article Content
Abstract
Background: Long acting reversible contraceptives (LARC) uptake have not been found to be impressive over the years, despite been a necessary tool in preventing maternal morbidity and mortality.
Aim: The study aimed at determining the uptake of LARC at the Federal Medical Centre, Yenagoa (FMCY), sociodemographics, previous contraceptive method used, current choice of LARC, source of information and associations between selected client characteristics and the choice of LARC.
Methodology: This was a descriptive retrospective study of clients who visited the family planning unit of the FMCY, from 1st January, 2018 to 1st January, 2021. A list of clients was obtained from the family planning unit register and case notes were retrieved. For this study, 181 case notes were gotten and data were collected using a proforma. P-value < 0.05 was significant.
Results: A total of 1,281 clients accepted the available family planning methods during the study period. About 14.1% accepted LARC. Majority (32.6%) of the clients were 30 - 34 years of age. Implanon and Jadelle were the commonly used methods (36.6%). Health personnel formed the highest source of LARC information. The reason for the choice of LARC for more than half of the clients was for child spacing (56.9%). There were no significant association between level of education, parity and the choice of contraceptive methods.
Conclusion: The uptake of LARC at the FMCY is low. Injectable contraceptives constituted majority of LARC uptake. Adolescents, the less educated and low parity clients rarely access the family planning clinic.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Cameron ST. Contraception and Sterilization. In: Edmonds DK, Lees C, Bourne T, editors. Dewhurst’s Textbook of Obstetrics and Gynaecology. 9th edition. John Wiley and sons Ltd; 2018. p. 939 - 952.
II. World Population Prospects– Population Division-United Nations. Available at: https://population.un.org/wpp/. Accessed on 20th July 2021.
III. Oranu EO, Ojule JD. A Decade of Jadelle Subdermal Implant Contraception in a Tertiary Health Institution in Port Harcourt, Southern Nigeria. J Biosci Med. 2018; 6(3): 123 - 130.
IV. The Federal Republic of Nigeria. Nigeria Demographic and Health Survey 2018 National Population Commission Abuja, Nigeria. 2019. Available at: www.DHSprogram.com. Accessed on 17 December 2020.
V. Practice Bulletin No. 186 Summary: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Obstet Gynecol. 2017; 130(5): 1173 - 1175.
VI. Sunday AA, Olusola AO, Oluwaseyi DS. Trends, patterns and determinants of long-acting reversible methods of contraception among women in sub - Saharan Africa. PLoS One. 2019; 14(6): e0217574.
VII. NICE 2013. National Collaborating Centre for Women’s and Children’s Health Commissioned by the National Institute for Health and Clinical Excellence (NICE update) 2013 https://www.nice. org.uk>. Accessed on 15 August, 2021
VIII. Cameron S. Contraception and abortion. In: Bickerstaff H, Kenny LC, editors. Gynaecology by ten teachers. 20th edition: CRC Press; 2017. p. 69 - 90
IX. Okafor II. Uptake of Long-Acting Reversible Contraceptive Methods in Enugu State University Teaching Hospital Enugu, South-East, Nigeria. Divers Equal Health Care. 2016; 13(3): 216 - 220.
X. Jumbo CH, Muhammad RB, Adewole ND, Isah DA, Offiong RA, Abdullahi HI. Uptake of long-acting reversible contraceptives in north central Nigeria: a five-year review. Int J Res Med Sci. 2021; 9: 1335 - 1339.
XI. Egede JO, Onoh RC, Umeora OU, Iyoke CA, Dimejesi IB, Lawani LO. Contraceptive prevalence and preference in a cohort of south–east Nigerian women. Patient Prefer. Adherence. 2015; 9: 707 - 714.
XII. Curtis KM, Tepper NK, Jatlaoui TC. US medical eligibility criteria for contraceptive use, 2016. MMWR Morb Mortal Wkly Rep. 2016; 65(3): 1 - 104.
XIII. Parks C, Peipert JF. Eliminating health disparities in unintended pregnancy with long-acting reversible contraception (LARC). Am J Obstet Gynecol. 2016; 214(6): 681 - 688.
XIV. Eke AC, Alabi-Isama L. Long acting reversible contraception (LARC) use among adolescent females in secondary institutions in Nnewi, Nigeria. J Obstet Gynaecol. 2011; 31(2): 164 – 168.
XV. Susan O, Gathari N, Collins O. Long-Acting Reversible Contraception Uptake and Associated Factors among Women of Reproductive Age in Rural Kenya. Int J Environ Res Public Health. 2019; 16(9): 1543.
XVI. Mohammed DA, Joel A, Bature S, Abubakar A, Mohammed C, Taingson M. Uptake and Predictors of Long-Acting Reversible Contraceptives among Women in a Tertiary Health Facility in Northern Nigeria. J Basic Clin Reprod Sci. 2017; 6(2): 80 - 84.
XVII. Disney EA, Sanders JN, Turok DK, Gawron LM. Preconception Counseling, Contraceptive Counseling, and Long-Acting Reversible Contraception Use in Women with Type I Diabetes: A Retrospective Cohort Study. Womens Health Rep. 2020; 1(1): 334 - 340.
XVIII. Isa B, Sanusi MI, Mairo M, Babagana B. Uptake and reason for discontinuation of long-acting reversible contraception in a tertiary hospital: A 5 years retrospective review. Afr. J. Med. Health Sci. 2020; 19(9): 142 - 149.
XIX. Anyanwu M, Alida BW. Uptake of long-acting reversible contraceptive devices in western region of The Gambia. Afri Health Sci. 2017; 17(2): 409 - 417.
XX. Fasubaa O, Sowemimo O, Ayegbusi O, AbdurRahim Z, Idowu B, Ayobami O, et al. Contributions of uterine fibroids to infertility at Ile-Ife, SouthWestern Nigeria. Trop J Obstet Gynaecol. 2018; 35(3): 266.
XXI. Mohammed DA, Joel A, Bature S, Abubakar A, Mohammed C, Taingson M. Uptake and Predictors of Long-Acting Reversible Contraceptives among Women in a Tertiary Health Facility in Northern Nigeria. J. Basic Clin. Reprod. Sci. 2017; 6(2): 80 - 84.